Modulation of Autophagy by Sorafenib: Effects on Treatment Response

The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment of hepatocellular carcinoma (HCC), one of the most lethal types of cancer worldwide. However, the increase in the number of sorafenib tumor resistant cells reduces efficiency. A better knowledge of the intra...

Descripción completa

Detalles Bibliográficos
Autores principales: Prieto-Domínguez, Nestor, Ordóñez, Raquel, Fernández, Anna, García-Palomo, Andres, Muntané, Jordi, González-Gallego, Javier, Mauriz, José L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896953/
https://www.ncbi.nlm.nih.gov/pubmed/27375485
http://dx.doi.org/10.3389/fphar.2016.00151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896953/
https://www.ncbi.nlm.nih.gov/pubmed/27375485
http://dx.doi.org/10.3389/fphar.2016.00151

Ejemplares similares